Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Critics Say S. Korea Drug Makers Need To Add Innovative Drugs

This article was originally published in PharmAsia News

Executive Summary

Some South Korean pharmaceutical companies can expect to jump in sales as they take advantage of global blockbuster drugs losing their patent protection. Dong A, Hanmi, Yuhan and Greencross have recent generic releases to spur that jump, but smaller firms are expected to fall farther behind, according to an analyst. South Korea's pharmaceutical industry has a chance to remake its tarnished image and expand its share of the global market expected to more than double by 2020, with a 9 percent increase expected in South Korea alone. But critics of the industry say it needs to move beyond generics and make new innovative drugs if it is to take advantage of the expected explosion in the demand for medicines. (Click here for more

You may also be interested in...

South Korea-U.S. Free Trade Agreement Likely To Put Stranglehold On Local Korean Drug Makers

SEOUL - South Korean pharmaceutical companies are bracing for a tough time ahead if the governments of South Korea and the U.S. ratify a long-awaited Free Trade Agreement hammered out last year after eight rounds of negotiations between the two countries

Sanofi-Aventis Loses Patent Lawsuit In Korea Over Oxaliplatin

SHANGHAI - Sanofi-Aventis lost a patent lawsuit in South Korea, after the country's Supreme Court dismissed its appeal to nullify patents obtained by Korea-based Boryung Pharmaceutical for its generic drug for colorectal cancer, Boryung announced Oct. 20

New US FDA Commissioner Stephen Hahn Heads to White Oak Under Vaping Cloud

Bipartisan Senate confirmation vote comes despite concerns about Stephen Hahn's non-answers to e-cigarette regulation questions.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts